Clinical trials based on this preclinical research eventually led to the U.S. Food and Drug Administration approval of the FTI lonafarnib (brand name Zokinvy) for HGPS, MAD-B, and related progeroid syndromes with accumulation of prelamin A variants [46–48]. The gene discussed is ZMPSTE24; the disease is progeroid syndrome.